ABSTRACT
Livedoid vasculopathy (LV) is a cutaneous manifestation of several diseases that lead to noninflammatory thrombosis of dermal vessels. We report the case of a 26-year-old female with a 4 years and 8 months-old history of diagnosis of LV and a non-healing ulcer of more than a year of evolution. Because of refractory response to standard care, low-pressure hyperbaric oxygen (LPHBOT) was added to the therapeutic scheme (azathiopine 2.5 mg/kg, folic acid and acetylsalicylic acid). After 12 sessions of LHBOT (60 min, 1.45 ATA ≈ 100% O2), ulcers achieved complete healing with significant pain relief and no recurrence was present over 6 months. More studies are necessary to determine the effectiveness of HBOT for LV treatment.
La vasculopatía livedoide (VL) es una manifestación cutánea de varias enfermedades que conducen a una trombosis no inflamatoria de los vasos dérmicos. Se presenta el caso de una mujer de 26 años con antecedente de diagnóstico de vasculopatía livedoide de 4 años y 8 meses, además de una úlcera no cicatrizante de más de un año de evolución. Debido a la respuesta refractaria a la atención estándar, se añadió oxígeno hiperbárico a baja presión (LPHBOT) al esquema terapéutico (azatriopina 2.5 mg/kg, ácido fólico y ácido acetilsalicílico). Después de 12 sesiones de LHBOT (60 min, 1,45 ATA ≈ 100% O2), las úlceras tuvieron una curación completa con un alivio significativo del dolor y no hubo recurrencia durante 16 meses. Se necesitan más estudios para determinar la eficacia de TOHB para el tratamiento del VL.
Subject(s)
Hyperbaric Oxygenation , Livedoid Vasculopathy , Thrombosis , Adult , Aspirin/therapeutic use , Female , Humans , Infant , Wound HealingABSTRACT
Abstract Livedoid vasculopathy (LV) is a cutaneous manifestation of several diseases that lead to non-inflammatory thrombosis of dermal vessels. We report the case of a 26-year-old female with a 4 years and 8 months-old history of diagnosis of LV and a non-healing ulcer of more than a year of evolution. Because of refractory response to standard care, low-pressure hyperbaric oxygen (LPHBOT) was added to the therapeutic scheme (azathiopine 2.5 mg/kg, folic acid and acetylsalicylic acid). After 12 sessions of LHBOT (60 min, 1.45 ATA ≈100% O2), ulcers achieved complete healing with significant pain relief and no recurrence was present over 6 months. More studies are necessary to determine the effectiveness of HBOT for LV treatment.
Resumen La vasculopatía livedoide (VL) es una manifestación cutánea de varias enfermedades que conducen a una trom bosis no inflamatoria de los vasos dérmicos. Se presenta el caso de una mujer de 26 años con antecedente de diagnóstico de vasculopatía livedoide de 4 años y 8 meses, además de una úlcera no cicatrizante de más de un año de evolución. Debido a la respuesta refractaria a la atención estándar, se añadió oxígeno hiperbárico a baja presión (LPHBOT) al esquema terapéutico (azatriopina 2.5 mg/kg, ácido fólico y ácido acetilsalicílico). Después de 12 sesiones de LHBOT (60 min, 1,45 ATA ≈100% O2), las úlceras tuvieron una curación completa con un alivio significativo del dolor y no hubo recurrencia durante 16 meses. Se necesitan más estudios para determinar la eficacia de TOHB para el tratamiento del VL.
ABSTRACT
Se estima que 15 a 20 % de los adultos padece infertilidad. Se presenta una revisión narrativa sobre elpapel y futuras perspectivas de la Terapia de Oxígeno Hiperbárico (TOHB) en el tratamiento de la in-fertilidad femenina y masculina. TOHB podría mejorar la disfunción eréctil de origen vascular, prevenirla afección espermática, la infertilidad secundaria al estrés oxidativo, la injuria por isquemia/reperfusióntesticular, y en consecuencia mejorar la calidad del esperma. El oxígeno hiperbárico podría estimularla ovogénesis, mejorar la calidad de los óvulos y del endometrio, disminuir la inflamación en la endo-metritis y así favorecer el proceso de fertilización fisiológica y asistida. Si bien son necesarios estudiosclínicos adicionales, TOHB podría ser a futuro una herramienta terapéutica útil en el tratamiento de lainfertilidad (AU)
It is estimated that 15 to 20% of adults suffer infertility. It is presented a narrative review about the role and future pers-pectives of hyperbaric oxygen therapy (HBOT) for infertility treatment. HBOT could improve erectile vascular dysfunc-tion, prevent sperm injury and infertility secondary to oxidative stress, and attenuate testicular ischemia/reperfusioninflammation, improving sperm quality. Hyperbaric oxygen stimulates oogenesis, improves the quality of the oocytes andendometrium, and decreases chronic inflammation in endometritis, so it favors the physiological and assisted fertilizationprocess. Although additional clinical studies are necessary, HBOT could be a future therapeutic tool for infertility treat-ment. (AU)
Subject(s)
Humans , Infertility , Erectile Dysfunction , Hyperbaric Oxygenation , PatientsABSTRACT
BACKGROUND: Hyperbaric oxygen (HBO2) therapy has been proposed to treat hypoxaemia and reduce inflammation in COVID-19. Our objective was to analyse safety and efficacy of HBO2 in treatment of hypoxaemia in patients with COVID-19 and evaluate time to hypoxaemia correction. METHODS: This was a multicentre, open-label randomised controlled trial conducted in Buenos Aires, Argentina, between July and November 2020. Patients with COVID-19 and severe hypoxaemia (SpO2 ≤90% despite oxygen supplementation) were assigned to receive either HBO2 treatment or the standard treatment for respiratory symptoms for 7 days. HBO2 treatment was planned for ≥5 sessions (1 /day) for 90 min at 1.45 atmosphere absolute (ATA). Outcomes were time to normalise oxygen requirement to SpO2 ≥93%, need for mechanical respiratory assistance, development of acute respiratory distress syndrome and mortality within 30 days. A sample size of 80 patients was estimated, with a planned interim analysis after determining outcomes on 50% of patients. RESULTS: The trial was stopped after the interim analysis. 40 patients were randomised, 20 in each group, age was 55.2±9.2 years. At admission, frequent symptoms were dyspnoea, fever and odynophagia; SpO2 was 85.1%±4.3% for the whole group. Patients in the treatment group received an average of 6.2±1.2 HBO2 sessions. Time to correct hypoxaemia was shorter in treatment group versus control group; median 3 days (IQR 1.0-4.5) versus median 9 days (IQR 5.5-12.5), respectively (p<0.010). OR for recovery from hypoxaemia in the HBO2 group at day 3 compared with the control group was 23.2 (95% CI 1.6 to 329.6; p=0.001) Treatment had no statistically significant effect on acute respiratory distress syndrome, mechanical ventilation or death within 30 days after admission. CONCLUSION: Our findings support the safety and efficacy of HBO2 in the treatment of COVID-19 and severe hypoxaemia. TRIAL REGISTRATION NUMBER: NCT04477954.
